ITRM
Iterum Therapeutics plc
Biotechnology
Market Cap$2M
5Y Perf.-100.0%
Compare Stocks
2 / 10Try these comparisons:
Stock Comparison
ITRM vs SPRO
Revenue, margins, valuation, and 5-year total return — side by side.
SPRO
Spero Therapeutics, Inc.
Biotechnology
Market Cap$141M
5Y Perf.-80.2%
ITRM vs SPRO — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | ITRM | SPRO |
|---|---|---|
| Industry | Biotechnology | Biotechnology |
| Market Cap | $2M | $141M |
| Revenue (TTM) | $390K | $36M |
| Net Income (TTM) | $-27M | $-44M |
| Gross Margin | -171.3% | -202.6% |
| Operating Margin | -52.0% | -130.9% |
| Forward P/E | — | 3.7x |
| Total Debt | $46M | $4M |
| Cash & Equiv. | $24M | $53M |
ITRM vs SPRO — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
ITRM
SPRO
| Stock | May 20 | Mar 26 | Return |
|---|---|---|---|
| Iterum Therapeutics… (ITRM) | 100 | 0.0 | -100.0% |
| Spero Therapeutics,… (SPRO) | 100 | 19.8 | -80.2% |
Price return only. Dividends and distributions are not included.
Quick Verdict: ITRM vs SPRO
Each card shows where this stock fits in a portfolio — not just who wins on paper.
Bottom line: SPRO leads in 3 of 6 categories, making it the strongest pick for profitability and margin quality and capital preservation and lower volatility. Iterum Therapeutics plc is the stronger pick specifically for growth and revenue expansion and operational efficiency and capital deployment. As sector peers, any of these can serve as alternatives in the same allocation.
ITRM
Iterum Therapeutics plc
The Growth Play
ITRM is the clearest fit if your priority is growth exposure.
- EPS growth 57.4%
- 14.8% revenue growth vs SPRO's -53.8%
- -74.8% ROA vs SPRO's -80.9%, ROIC -117.8% vs -327.2%
Best for: growth exposure
SPRO
Spero Therapeutics, Inc.
The Income Pick
SPRO carries the broadest edge in this set and is the clearest fit for income & stability and long-term compounding.
- beta 0.90
- -78.2% 10Y total return vs ITRM's -100.0%
- Lower volatility, beta 0.90, Low D/E 9.3%, current ratio 2.19x
Best for: income & stability and long-term compounding
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | ITRM | 14.8% revenue growth vs SPRO's -53.8% |
| Quality / Margins | SPRO | -122.6% margin vs ITRM's -69.1% |
| Stability / Safety | SPRO | Beta 0.90 vs ITRM's 1.49 |
| Dividends | Tie | Neither stock pays a meaningful dividend |
| Momentum (1Y) | SPRO | +334.3% vs ITRM's -96.6% |
| Efficiency (ROA) | ITRM | -74.8% ROA vs SPRO's -80.9%, ROIC -117.8% vs -327.2% |
ITRM vs SPRO — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
Segment breakdown not available.
FY 2024
ITRM vs SPRO — Financial Metrics
Side-by-side numbers across 2 stocks — who leads on profitability, valuation, growth, and risk.
BEST OVERALLSPROLAGGINGITRM
ITRMIterum Therapeutics p…
0leads
SPROSpero Therapeutics, I…
5leads
6 Total Categories
CATEGORYLEADERvs ITRMMETRICS WON
Income & Cash FlowRevenue, margins, and cash flow strength
SPRO4/5
Valuation MetricsMultiples, price ratios, and targets
SPRO1/1
Profitability & EfficiencyROE, ROIC, leverage, and quality scores
SPRO3/5
Total Returns1Y, 3Y, 5Y total returns with dividends
SPRO6/6
Risk & VolatilityBeta, volatility, and downside exposure
SPRO2/2
Analyst OutlookRatings, price targets, and dividends
—
—
Income & Cash Flow (Last 12 Months)
SPRO leads this category, winning 4 of 5 comparable metrics.
Income & Cash Flow (Last 12 Months)
SPRO is the larger business by revenue, generating $36M annually — 91.7x ITRM's $390,000. Profitability is closely matched — net margins range from -122.6% (SPRO) to -69.1% (ITRM).
| Metric | ITRMIterum Therapeuti… | SPROSpero Therapeutic… |
|---|---|---|
| RevenueTrailing 12 months | $390,000 | $36M |
| EBITDAEarnings before interest/tax | -$19M | -$45M |
| Net IncomeAfter-tax profit | -$27M | -$44M |
| Free Cash FlowCash after capex | -$20M | -$28M |
| Gross MarginGross profit ÷ Revenue | -171.3% | -2.0% |
| Operating MarginEBIT ÷ Revenue | -52.0% | -130.9% |
| Net MarginNet income ÷ Revenue | -69.1% | -122.6% |
| FCF MarginFCF ÷ Revenue | -51.1% | -77.4% |
| Rev. Growth (YoY)Latest quarter vs prior year | — | -77.4% |
| EPS Growth (YoY)Latest quarter vs prior year | +33.3% | +59.4% |
SPRO leads this category, winning 4 of 5 comparable metrics.
Valuation Metrics
SPRO leads this category, winning 1 of 1 comparable metric.
Valuation Metrics
| Metric | ITRMIterum Therapeuti… | SPROSpero Therapeutic… |
|---|---|---|
| Market CapShares × price | $2M | $141M |
| Enterprise ValueMkt cap + debt − cash | $23M | $93M |
| Trailing P/EPrice ÷ TTM EPS | -0.02x | -1.98x |
| Forward P/EPrice ÷ next-FY EPS est. | — | 3.75x |
| PEG RatioP/E ÷ EPS growth rate | — | — |
| EV / EBITDAEnterprise value multiple | — | — |
| Price / SalesMarket cap ÷ Revenue | — | 2.95x |
| Price / BookPrice ÷ Book value/share | — | 2.94x |
| Price / FCFMarket cap ÷ FCF | — | — |
SPRO leads this category, winning 1 of 1 comparable metric.
Profitability & Efficiency
SPRO leads this category, winning 3 of 5 comparable metrics.
Profitability & Efficiency
| Metric | ITRMIterum Therapeuti… | SPROSpero Therapeutic… |
|---|---|---|
| ROE (TTM)Return on equity | — | -165.5% |
| ROA (TTM)Return on assets | -74.8% | -80.9% |
| ROICReturn on invested capital | -117.8% | -3.3% |
| ROCEReturn on capital employed | -94.1% | -71.0% |
| Piotroski ScoreFundamental quality 0–9 | 1 | 1 |
| Debt / EquityFinancial leverage | — | 0.09x |
| Net DebtTotal debt minus cash | $21M | -$49M |
| Cash & Equiv.Liquid assets | $24M | $53M |
| Total DebtShort + long-term debt | $46M | $4M |
| Interest CoverageEBIT ÷ Interest expense | -10.61x | — |
SPRO leads this category, winning 3 of 5 comparable metrics.
Total Returns (Dividends Reinvested)
SPRO leads this category, winning 6 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in SPRO five years ago would be worth $1,870 today (with dividends reinvested), compared to $19 for ITRM. Over the past 12 months, SPRO leads with a +334.3% total return vs ITRM's -96.6%. The 3-year compound annual growth rate (CAGR) favors SPRO at 9.7% vs ITRM's -69.7% — a key indicator of consistent wealth creation.
| Metric | ITRMIterum Therapeuti… | SPROSpero Therapeutic… |
|---|---|---|
| YTD ReturnYear-to-date | -90.2% | +6.8% |
| 1-Year ReturnPast 12 months | -96.6% | +334.3% |
| 3-Year ReturnCumulative with dividends | -97.2% | +32.1% |
| 5-Year ReturnCumulative with dividends | -99.8% | -81.3% |
| 10-Year ReturnCumulative with dividends | -100.0% | -78.2% |
| CAGR (3Y)Annualised 3-year return | -69.7% | +9.7% |
SPRO leads this category, winning 6 of 6 comparable metrics.
Risk & Volatility
SPRO leads this category, winning 2 of 2 comparable metrics.
Risk & Volatility
SPRO is the less volatile stock with a 0.90 beta — it tends to amplify market swings less than ITRM's 1.49 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. SPRO currently trades 78.0% from its 52-week high vs ITRM's 2.4% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | ITRMIterum Therapeuti… | SPROSpero Therapeutic… |
|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 1.49x | 0.90x |
| 52-Week HighHighest price in past year | $1.28 | $3.22 |
| 52-Week LowLowest price in past year | $0.03 | $0.57 |
| % of 52W HighCurrent price vs 52-week peak | +2.4% | +78.0% |
| RSI (14)Momentum oscillator 0–100 | 29.6 | 46.6 |
| Avg Volume (50D)Average daily shares traded | 36.8M | 384K |
SPRO leads this category, winning 2 of 2 comparable metrics.
Analyst Outlook
Insufficient data to determine a leader in this category.
Analyst Outlook
| Metric | ITRMIterum Therapeuti… | SPROSpero Therapeutic… |
|---|---|---|
| Analyst RatingConsensus buy/hold/sell | — | Buy |
| Price TargetConsensus 12-month target | — | — |
| # AnalystsCovering analysts | — | 13 |
| Dividend YieldAnnual dividend ÷ price | — | — |
| Dividend StreakConsecutive years of raises | — | — |
| Dividend / ShareAnnual DPS | — | — |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | 0.0% |
Insufficient data to determine a leader in this category.
Key Takeaway
SPRO leads in 5 of 6 categories — strongest in Income & Cash Flow and Valuation Metrics.
Best OverallSpero Therapeutics, Inc. (SPRO)Leads 5 of 6 categories
Loading custom metrics...
ITRM vs SPRO: Frequently Asked Questions
8 questions · data-driven answers · updated daily
01Is ITRM or SPRO a better buy right now?
Analysts rate Spero Therapeutics, Inc.
(SPRO) a "Buy" — based on 13 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which is the better long-term investment — ITRM or SPRO?
Over the past 5 years, Spero Therapeutics, Inc.
(SPRO) delivered a total return of -81. 3%, compared to -99. 8% for Iterum Therapeutics plc (ITRM). Over 10 years, the gap is even starker: SPRO returned -78. 2% versus ITRM's -100. 0%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
03Which is safer — ITRM or SPRO?
By beta (market sensitivity over 5 years), Spero Therapeutics, Inc.
(SPRO) is the lower-risk stock at 0. 90β versus Iterum Therapeutics plc's 1. 49β — meaning ITRM is approximately 65% more volatile than SPRO relative to the S&P 500.
04Which is growing faster — ITRM or SPRO?
On earnings-per-share growth, the picture is similar: Iterum Therapeutics plc grew EPS 57.
4% year-over-year, compared to -395. 3% for Spero Therapeutics, Inc.. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
05Which has better profit margins — ITRM or SPRO?
Spero Therapeutics, Inc.
(SPRO) is the more profitable company, earning -142. 9% net margin versus -69. 1% for Iterum Therapeutics plc — meaning it keeps -142. 9% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: SPRO leads at -152. 9% versus -52. 0% for ITRM. At the gross margin level — before operating expenses — SPRO leads at -101. 7%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
06Which pays a better dividend — ITRM or SPRO?
None of the stocks in this comparison currently pay a material dividend.
All are effectively zero-yield and should be held for capital appreciation rather than income.
07Is ITRM or SPRO better for a retirement portfolio?
For long-horizon retirement investors, Spero Therapeutics, Inc.
(SPRO) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 90)). Both have compounded well over 10 years (SPRO: -78. 2%, ITRM: -100. 0%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
08What are the main differences between ITRM and SPRO?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform both.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.